CogRx is dedicated to the discovery and development of small molecule therapeutics targeting the toxic proteins that underlie Alzheimer’s disease and other neuro-degenerative diseases. The company’s lead candidate, CT1812, is currently in clinical testing in individuals with mild to moderate Alzheimer's disease. This small molecule drug that has demonstrated an ability to prevent toxic beta-amyloid oligomers from binding to receptor proteins in the brain. CT1812 has been shown to reverse the memory loss in Alzheimer’s mouse models after one month of treatment, and to sustain this memory recovery for six months. CT1812 is the first drug ever reported to target these toxic oligomers and stop their deleterious effects on memory.